Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential.

Patents show all

9Applications

SEC Filings show all

D2

Contact Information

200 Cambridge Park Drive, Suite 3100
Cambridge, MA 02140
United States

(617) 843-5032

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $92,300,0001-102017-03-15Operating

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2017-03-15$15,000,000Debt_financingSquare 1 Bank
    2015-06-11$65,000,000VentureNew Leaf Venture PartnersCowen Group, Jennison Associates, F-Prime Capital Partners, Sanofi-Genzyme BioVentures, Brace Pharma Capital, Novo A/S, Atlas Venture, Seattle Genetics, Sectoral Asset Management, Wellington Management, Sabby Management
    2014-10-21$12,300,000VentureF-Prime Capital Partners, Atlas VentureSanofi-Genzyme BioVentures

    SEC Form D Funding Events

    DateOfferedSoldType
    2014-10-20$12,252,685$6,252,685Equity

    Key Executives

    • Charles Wilson
      Executive Officer, Director
    • Ben Auspitz
      Director
    • Bruce Booth
      Director